FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Megestrol Acetate (Megace) Oral Suspension
Status: Discontinuation
»Therapeutic Categories: Endocrinology/Metabolism

Expand all

Bristol Myers Squibb Co. (New 05/06/2019)

Company Contact Information:

Presentation Posting Date Related Information
40 mg/mL Oral Suspension (NDC 00015-508-42) 05/06/2019

Endo Pharmaceuticals, Inc. (New 08/21/2019)

Company Contact Information:

Presentation Posting Date Related Information
MEGACE®ES 625mg/5ml Suspension (NDC 63481-160-38) 08/21/2019 Endo has made a business decision to permanently discontinue the drug product.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English